DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research

NAVIGATOR logo


Publications (3 of 24)


Search Publications :

2012

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
David Preiss, Laine E Thomas, Jie-Lena Sun, Steven M Haffner, Rury R Holman, Eberhard Standl, Lawrence A Leiter, Theodore Mazzone, Guy E Rutten, Gianni Tognoni, Felipe A Martinez, Fu-Tien Chiang, Robert M Califf, John J McMurray
BMJ Open 2012;2:e001925. Published:30-Nov-2012. Epub:30-Nov-2012. PMID:23204139. doi:10.1136/bmjopen-2012-001925

Correspondence: Prediabetes and the risk of diabetes
John JV McMurray, Steven M Haffner, Robert M Califf, Rury R Holman
The Lancet 2012;380:1225-1226. Published:06-Oct-2012. PMID:23040850. doi:10.1016/S0140-6736(12)61706-1

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
John J.V. McMurray, Robert M. Califf, Angelyn M. Bethel, Steven M. Haffner, Rury R. Holman
The Journal of Clinical Hypertension 2012;14:731. Published:Oct-2012. Epub:26-Jul-2012. PMID:23031154. doi:10.1111/j.1751-7176.2012.00687.x